Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 155 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Samples
- 155 samples: 136 distinct titles, 15 of them repeatedGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE97682_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA382641 and SRA study SRP103825. Searching any of these in the dataset finder brings you back here.
How we read this: Read from 155 sample titles: 136 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM2575272 4weeks_mix_10
- GSM2575273 4weeks_neg_09
- GSM2575274 4weeks_neg_10
- GSM2575275 4weeks_mix_09
- GSM2575276 1week_mix_10
- GSM2575277 1week_mix_09
- GSM2575278 nodrug_mix_09
- GSM2575279 nodrug_mix_10
- GSM2575280 nodrug_mix_02
- GSM2575281 4weeks_EGFR_10
- GSM2575282 4weeks_EGFR_09
- GSM2575283 1week_EGFR_10
- GSM2575284 1week_EGFR_09
- GSM2575285 nodrug_EGFR_10
- GSM2575286 nodrug_EGFR_09
- GSM2575287 nodrug_EGFR_02
- GSM2575288 EGFR-p9-noDrug_ATAC-seq
- GSM2575289 EGFR-p9-week1_ATAC-seq
- GSM2575290 EGFR-p9-week4_ATAC-seq
- GSM2575291 EGFR-p14-noDrug-v2_ATAC-seq
- GSM2575292 EGFR-p14-week1-v2_ATAC-seq
- GSM2575293 EGFR-p14-week4-v2_ATAC-seq
- GSM2575294 EGFR-week5-v2_ATAC-seq
- GSM2575295 mix-p9-noDrug_ATAC-seq
- GSM2575296 mix-p9-week1_ATAC-seq
- GSM2575297 mix-p9-week4_ATAC-seq
- GSM2575298 mix-p14-noDrug-v2_ATAC-seq
- GSM2575299 mix-p14-week1-v2_ATAC-seq
- GSM2575300 mix-p14-week4-v2_ATAC-seq
- GSM2575301 mix-week5-v2_ATAC-seq
- GSM2575302 neg-p9-week4_ATAC-seq
- GSM2575303 neg-p14-week4-v2_ATAC-seq
- GSM2575304 neg-week5-v2_ATAC-seq
- GSM2575305 A6_ColonyC2_Drug
- GSM2575306 A6_ColonyC2_NoDrug
- GSM2575307 A6_ColonyC3_Drug
- GSM2575308 A6_ColonyC3_NoDrug
- GSM2575309 A6_ColonyE2_Drug
- GSM2575310 A6_ColonyE2_NoDrug
- GSM2575311 A6_ColonyE3_Drug
+ 115 more — browse all 155 samples with per-sample file links →
- GSE300628 HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies 60 samples shares resistance, mode
- GSE254366 Epigenome reprogramming through H3K27 and H3K4 trimethylation as a resistance mechanism to DNA methylation inhibition in BRAFV600E-mutated CRC. 36 samples shares reprogramming, resistance
- GSE282423 Imaging-based drug screening combined with moleuclar profiling identifies signatures and drivers of therapy resistance in pediatric AML [RNA-seq] 28 samples shares resistance, drug
- GSE280381 Investigating therapy-induced senescence as a reversible escape mechanism of drug resistance in breast cancer cells using high-dose doxorubicin treatment 12 samples shares resistance, drug
- GSE291147 Mapping convergent regulators of melanoma drug resistance by PerturbFate 320 samples shares resistance, drug
- GSE282258 Imaging-based drug screening combined with moleuclar profiling identifies signatures and drivers of therapy resistance in pediatric AML [ATAC-seq] 44 samples shares resistance, drug
- GSE326661 Reprogramming engineered autologous T cells to overcome resistance in Merkel cell carcinoma [scRNA-seq] 22 samples shares reprogramming, resistance
- GSE308647 Drug tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms 15 samples shares resistance, drug
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.